5 top ASX 200 stocks that brokers rate as buys after the market selloff

These stocks could be top buys for investors looking to add to their portfolio.

| More on:
Man presses green buy button and red sell button on a graph.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are on the lookout for some investment ideas, then it could be worth checking out what analysts saying.

Listed below are five ASX 200 stocks that leading brokers currently rate as buy. Here's what they are recommending to clients:

James Hardie Industries plc (ASX: JHX)

Bell Potter sees housing and renovation trends in North America as a tailwind for James Hardie, the fibre cement building materials specialist. It has a buy rating and $63.00 price target on its shares. The broker continues to like the company's exposure to structural housing demand. It said: "In our view, JHX is poised for continued earnings expansion, driven by the structural shift towards fibre cement in the US. Households in the US continue to shift to fibre cement cladding from vinyl/timber, providing a multi-year runway for JHX's revenue and profit growth."

ResMed Inc. (ASX: RMD)

Medical device company ResMed could be an ASX 200 stock to buy. The team at Macquarie is bullish and sees plenty of value in its shares at current levels. And with its market leadership in CPAP devices and strong recurring revenue model, Macquarie remains confident in its long-term growth story. The broker has an outperform rating and $45.10 price target.

Telix Pharmaceuticals Ltd (ASX: TLX)

A third ASX 200 stock that could be a top buy is Telix. It has impressed in recent times with its strong earnings growth and a pipeline packed with potential lucrative therapies. Bell Potter is a big fan and highlights its established revenue stream from Illuccix and sees future product approvals (like Gozellix and Zircaix) as key drivers of potential upside. It also notes that its current valuation leaves room for meaningful gains if the company delivers on its plans. Bell Potter has a buy rating and $36.00 price target on its shares.

WiseTech Global Ltd (ASX: WTC)

Macquarie is also bullish on logistics software giant WiseTech, noting its strong market position and structural growth prospects. The broker highlights that the company is optimising for long-term value creation and feels investors should be patient following recent product launch delays. The broker has an outperform rating and $152.70 price target on its shares.

Xero Ltd (ASX: XRO)

Finally, Goldman Sachs thinks that Xero could be a top ASX 200 stock for investors to buy. The broker sees it as a long-term compounder in the cloud accounting space, previously highlighting a multi-decade runway for growth. This is thanks to its total addressable market sitting at about 100 million small to medium sized businesses, compared to its current subscriber base of approximately 4 million. Goldman has a buy rating and $201.00 price target on Xero's shares.

Motley Fool contributor James Mickleboro has positions in ResMed, WiseTech Global, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Macquarie Group, ResMed, Telix Pharmaceuticals, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group, ResMed, WiseTech Global, and Xero. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Happy young couple saving money in piggy bank.
Broker Notes

Invest $500 in these top ASX shares in May

Analysts think these shares could be in the buy zone for the month ahead.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Broker Notes

These ASX 200 shares could rise 30% to 40%

Let's see what analysts are saying about these buy-rated shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Business people discussing project on digital tablet.
Materials Shares

What does Macquarie think Liontown Resources shares are worth?

Let's see if analysts think that this lithium miner is in the buy zone or best avoided.

Read more »

Man presses green buy button and red sell button on a graph.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

What does Macquarie think ResMed shares are worth?

Does the broker see value in this blue chip? Let's find out.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Broker Notes

These ASX 200 shares could rise 30% to 70%

Let's see which shares analysts are tipping to generate big returns.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »